All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Maryland · House · Senate · $40,000.00 income · posted Jul 15, 2026

Official filing document

Bills named in this filing 2

HR 8800
National Defense Authorization Act for Fiscal Year 2027
S 4784
National Defense Authorization Act for Fiscal Year 2027

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Defense

S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.